

Supporting Information

Jin et al. 10.1073/pnas.1213819110

SI Materials and Methods

Reagents and Antibodies. Antibodies to Ubc12, phospho-Erk1/2, phospho-p38, p38, and phospho-PLC γ 1 were purchased from Cell Signaling Technology. Antibodies to ZAP-70, I κ B- α , Erk2, Cullin-1, Shc, Grb2, and HA were purchased from Santa Cruz Biotechnology. Anti-FLAG antibody was purchased from Sigma-Aldrich. All fluorochrome-tagged antibodies were purchased from eBioscience. MLN4924 was purchased from Active Biochem. CellTrace Violet and EdU (5-ethynyl-2'-deoxyuridine) were purchased from Invitrogen.

DNA Constructs. Plasmids to express HA-NEDD8, RGS-Ubc12, and p66Shc were obtained from Addgene. To generate the FLAG-tagged versions of p66Shc, p52Shc, and p46Shc, the p66Shc cDNA was PCR-amplified and subcloned into pCS2-FLAG vector. Point mutation was generated using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. WT p52Shc and K3R p52Shc cDNAs were cloned into pMIG retroviral vectors and used to transduce primary CD4⁺ T cells. For construction of shRNA expression vectors, oligonucleotides were cloned in the LMP vector according to the manufacturer's protocol (Open Biosystems). Oligonucleotide sequences were as follows: Ubc12 shRNA, 5'-TGCTGTTGACAGTGAGCGCCCTGATGAAGGCTTCTACAAATAGTGAAGCCACAGATGTATTTGTAGAAGCCTTCATCAGGATGCCTACTGCTCGGA-3'; Nedd8 shRNA, 5'-TGCTGTTGACAGTGAGCGAACAGACAAGGTGGAGCGAATCTAGTGAAGCCACAGATGTAGATTCGCTCCACCTTGTCTGTGTGCCTACTGCTCGGA-3'; Nae1 shRNA, 5'-TGCTGTTGACAGTGAGCGCTCATGTTTGCTTAATAAATTAGTGAAGCCACAGATGTAATTTATTAAGCAAACATGAGCATGCCTACTGCTCGGA-3'.

T-Cell Proliferation and IL-2 Production. FACS-sorted CD4⁺ T cells were activated with various concentrations of anti-CD3 (clone 145-2C11; BioLegend) and anti-CD28 (clone 37.1; Bio X Cell). T-cell proliferation was assessed by EdU labeling according to the manufacturer's instructions (Invitrogen), followed by flow cytometry or, alternatively, the addition of 1 μ Ci/mL of ³H-thymidine,

with cell-incorporated radiation monitored by a β -plate counter. Cell division was analyzed by prelabeling CD4⁺ T cells with 5 μ M CellTrace Violet (Invitrogen). IL-2 production was analyzed by ELISA or intracellular staining.

Th-Cell Differentiation in Vitro. Purified naive CD4⁺ T cells from control or shUbc12-expressing chimeric mice were stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of irradiated splenocytes. Cells were polarized into Th1 cells by culturing with human rIL-2 (100 U/mL), mouse IL-12 (10 ng/mL; Peprotech), and anti-mouse IL-4 antibody (10 μ g/mL; BD Biosciences), or into Th2 cells by culturing with human rIL-2 (100 U/mL), mouse IL-4 (20 ng/mL; Peprotech), anti-mouse IL-12 antibody (10 μ g/mL; BD Biosciences), and anti-mouse IFN- γ antibody (10 μ g/mL; BD Biosciences).

Generation of Stable Cell Lines by Lentiviral Infection. Full-length human NEDD8 cDNA (aa 1–76) was subcloned into pLENTI6/V5-DEST lentiviral expression vector (Invitrogen) in frame with an N-terminal 3 \times FLAG epitope. The resulting plasmids were packaged into virus particles using the ViraPower Lentiviral Expression System (Invitrogen). Jurkat E6.1 cells were infected with lentivirus together with 5 μ g/mL polybrene by centrifuging cells at 420 \times g for 60 min. After infection, cells were selected in the presence of blasticidin for 2 wk.

Immunoprecipitation and Immunoblotting. Cell pellets were lysed in 2 \times Laemmli sample buffer. Cell lysates were resolved by SDS/PAGE and immunoblotted with the appropriate antibodies. For detection of NEDD8 conjugate proteins, cells were lysed with 1% SDS in Tris-buffered saline [50 mmol/L Tris (pH 7.5) and 150 mmol/L NaCl] supplemented with 10 mmol/L N-ethylmaleimide, incubated at 95 $^{\circ}$ C for 10 min, and then diluted to 0.1% SDS with Tris-buffered saline containing 1% Nonidet P-40. NEDD8-modified proteins were immunoprecipitated from diluted lysates using an anti-FLAG-M2 agarose bead (Sigma-Aldrich) for 4 h at 4 $^{\circ}$ C. The immunoprecipitates were eluted with triple-FLAG peptide. The eluates were subjected to Western blot analysis using the indicated antibodies.




Fig. S1. Normal T-cell development in Ubc12 knockdown mice, as demonstrated by phenotypic analysis of Ubc12 shRNA-expressing chimeric mice. (A) Flow cytometry analysis of thymocytes in control and Ubc12 shRNA-expressing chimeric mice stained with anti-CD4 and anti-CD8 ($n = 4$). (B) Flow cytometry analysis of splenocytes from control and Ubc12 shRNA-expressing chimeric mice for CD4 and CD8 expression ($n = 4$). (C) Representative FACS plot of CD4⁺-gated cells showing staining for CD62L and CD44. Lower percentages of CD4⁺ memory T cells (CD62L^{Low} and CD44^{High}) were observed in the spleens of Ubc12 knockdown chimeric mice compared with WT mice.




Fig. S2. Normal T-cell apoptosis by Ubc12 knockdown. Detection of 7-amino-actinomycin D (7-AAD)-positive apoptotic cells after 24 h of stimulation of CD4⁺ T cells with anti-CD3/CD28 mAbs. Numbers above the bracketed lines indicate the percentage of 7-AAD-positive cells.




Fig. S3. Knockdown of the NEDD8 components affects T-cell function. Inhibition of the NEDD8 pathway by shRNA-mediated simultaneous knockdown of Nae1, Ubc12, and NEDD8 is shown. (A) Retroviral vector bearing multiple shRNAs targeting multiple genes (Nae1, Ubc12, and NEDD8). The pLMP vector encodes for a miR30-based target-specific shRNA under LTR promoter control. (B) Western blots of cell lysates from GFP⁺CD4⁺ T cells expressing Nae1, Ubc12, or NEDD8 shRNA individually or combined (shTriple). (C) Decreased proliferation of CD4⁺ T cells sorted from shTriple-expressing chimeric mice. CD4⁺ T cells from control and shTriple-expressing chimeric mice were stimulated in vitro with anti-CD3/CD28 mAbs for 3 d. ³H-thymidine was added to the culture during the last 8 h, followed by measurement of incorporation. (D) Proliferation of control (*Left*) and shTriple-expressing (*Right*) CD4⁺ T cells assessed by CellTrace Violet division assay after stimulation with anti-CD3/CD28 mAbs. (E) Production of IL-2 from control and shTriple-expressing CD4⁺ T cells assessed by ELISA after stimulation with anti-CD3/CD28 mAbs for 2 d. (F) Proliferation of CD4⁺ T cells from Nae1 shRNA-expressing chimeric mice, measured as described above. (G) IL-2 production of CD4⁺ T cells from Nae1 shRNA-expressing chimeric mice, measured as described above.




Fig. 54. Effect of MLN4924 on NF- κ B activation. (A) CD4⁺ T cells were preactivated with anti-CD3 in the presence of 0.1 μ M MLN4924 for 16 h and then stimulated with phorbol 12-myristate 13-acetate (100 ng/mL) and ionomycin (1 μ M) for the indicated time periods. Cell lysates were separated by SDS/PAGE and immunoblotted with the indicated antibodies. Grb2 was used as a loading control. (B) Jurkat cells pretreated with 0.1 μ M MLN4924 for 16 h were stimulated with TNF- α (10 ng/mL).




Fig. 55. Identification of NEDD8-conjugated proteins by MS. (A) The 3 \times Flag-NEDD8 Δ GG denotes the NEDD8 mutant in which the last two glycine residues are deleted. To purify NEDD8-modified proteins under denaturing conditions, a JE6.1 stable cell line expressing 3 \times FLAG-NEDD8 or 3 \times FLAG-NEDD8 mutant (Δ GG) was lysed in 1% SDS lysis buffer and denatured at 100 $^{\circ}$ C, after which the SDS was diluted 10-fold with 1% Triton X-100 buffer and then immunoprecipitated with anti-FLAG-conjugated beads, followed by elution with triple FLAG peptide. The eluates were subjected to Western blot and MS analyses. (B) Silver staining of affinity-purified FLAG-NEDD8-modified proteins. (C) Proteins identified in the FLAG-NEDD8 sample, but not in the FLAG-NEDD8 mutant (Δ GG) sample.